Microscopic Polyangiitis Pipeline Global Therapeutics Landscape Review H2 2015

Press Release   •   Aug 27, 2015 09:55 EDT

Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2015 Adds “Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2015” which provides an overview of the Microscopic Polyangiitis pipeline.

This report provides comprehensive information on the therapeutic development for Microscopic Polyangiitis (MPA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Microscopic Polyangiitis (MPA) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H2, 2015 Pipeline Review of “Microscopic Polyangiitis” addition with 21 market data tables and 12 figures, spread across 49 pages is .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our professional's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Drugs Profile Discussed in this Research:

belimumab, CCX-168, immune globulin (human), rituximab biosimilar, rituximab biosimilar, rituximab biosimilar and rituximab biosimilar

Companies Discussed/Mentioned in this Research:

Aprogen, Inc., ChemoCentryx, Inc., Epirus Biopharmaceuticals, Inc., GlaxoSmithKline Plc, Panacea Biotec Limited, Sandoz International GmbH and Teijin Pharma Limited

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license).


  • The report provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Microscopic Polyangiitis (MPA) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Microscopic Polyangiitis (MPA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Microscopic Polyangiitis (MPA) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Microscopic Polyangiitis (MPA)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore More Research Report on Autoimmune Drugs Market.

Autoimmune diseases pose a severe problem. Basically, it is characterized by a reaction of the body against its own cells and tissues. Sometimes, the body may fail to recognize its own cells and tissues and then the antibodies react against body’s own cells and lead to a lot of problems. There are a lot of diseases that are characterized as autoimmune diseases and dealing with such problems requires thorough expertise.

Immunosuppressants are generally used as autoimmune drugs and serve to suppress the reaction of the body to its own cells. You can find a lot of these drugs and they may be specific for some diseases and thus a through knowledge of these autoimmune drugs is required for the sake of using it for recovering from this grave problem.

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries